CTI acquires BGO firm
Cyclotron developer CTI of Knoxville, TN, last month acquired Advanced Crystal Technology from Nihon Kessho Koogaku, a subsidiary of Mitsui Mining and Smelting. The deal helps CTI expand its PET imaging product portfolio, and gives it increased access to
Cyclotron developer CTI of Knoxville, TN, last month acquired Advanced Crystal Technology from Nihon Kessho Koogaku, a subsidiary of Mitsui Mining and Smelting. The deal helps CTI expand its PET imaging product portfolio, and gives it increased access to bismuth germanate (BGO), a key detector component in PET devices. ACT is the primary supplier of BGO to CTI PET Systems, the joint venture between CTI and Siemens Nuclear Medicine Group of Hoffman Estates, IL.
ACT is based in Rockford, TN, and was established in 1988. CTI will keep existing ACT employees at the Rockford site, but will move the companys marketing and R&D operations to CTIs corporate offices in Knoxville.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
